Advertisement


Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab

ESMO Congress 2022

Advertisement

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The CheckMate 914 trial compared nivolumab plus ipilimumab to placebo in patients who had undergone a nephrectomy for clear cell carcinoma and were at substantial risk of recurrence. The eligibility included patients who were pT2a high grade, any pT2b, any pT3, pT4, or N1 positive disease, and the patients were randomized one to one to Nivolumab, 240 mg IV every two weeks for 12 doses, ipilumumab 1 mg/kg IV every six weeks for four doses or matched placebo. The expected treatment duration of this study was six months. The trial randomized over 800 patients and the patient characteristics were quite balanced. The majority of patients, nearly 80%, fell into the pT3a category. The primary endpoint of the trial was disease-free survival by blind, independent central review, and at the time of the analysis, the trial did not reach the primary endpoint. The hazard ratio for comparison between the two arms was 0.92, and the P value was 0.53. The 24-month disease-free survival rate was 76% for NIVO plus IPI, and 74% for placebo. The adverse event profile for NIVO plus IPI was similar to that, which we had seen in the studying of advanced disease. However, few patients, relatively few, completed the full 12 courses of NIVO and four of IPI, only 57%. The proportion of patients that had treatment-related grade three or higher AEs was 28% for NIVO plus IPI, compared to 2% per placebo. This is actually a lower rate than we saw for NIVO plus IPI in the setting of metastatic disease, but the treatment discontinuation rate was relatively high in this trial in the adjuvant setting. Treatment adverse events were as expected. The most common was pruritus, fatigue, and diarrhea, as we'd expect for NIVO plus IPI, and the proportion of patients who required high dose steroids on this NIVO plus IPI program was 23%. In summary then, part A of CheckMate 914 trial, which compares NIVO plus IPI to placebo in patients with localized RCC at high risk of post-nephrectomy relapse did not meet the primary endpoint of disease-free survival. The safety profile of NIVO plus IPI was consistent with the known profile for the combination of advanced RCC. However, the rate of discontinuation due to treatment-related adverse events was considerable with NIVO plus IPI in the adjuvant setting. Further analysis underway to understand the outcome of CheckMate 914 with regard to the patient population studied, and there is a part B, which is essentially a separate trial that has a primary endpoint of comparing NIVO monotherapy to placebo. That study is ongoing.

Related Videos

Kidney Cancer

Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after nephrectomy; and CheckMate 914, which compared nivolumab monotherapy or nivolumab combined with ipilimumab vs placebo in patients with localized disease who underwent radical or partial nephrectomy and who are at high risk of relapse. (Abstract LBA4 & LBA66).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Breast Cancer
Immunotherapy

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Advertisement

Advertisement




Advertisement